| Revista: | Anais brasileiros de dermatologia |
| Base de datos: | |
| Número de sistema: | 000558067 |
| ISSN: | 0365-0596 |
| Autores: | Pacola, Paulo Rodrigo1 Rostey, Renato Roberto Liberato1 Rizzo, Fernanda de Figueiredo Arruda1 |
| Instituciones: | 1Hospital Universitário Júlio Muller, Department of Dermatology, Cuiabá, MT. Brasil |
| Año: | 2023 |
| Volumen: | 98 |
| Número: | 5 |
| Paginación: | 587-594 |
| País: | Brasil |
| Idioma: | Inglés |
| Resumen en inglés | Background Bleomycin is a chemotherapeutical drug used to treat several neoplasias, including non-melanoma skin cancer; it is effective in the treatment of basal cell carcinoma (BCC) via intralesional infiltration. Transdermal drug delivery, which includes technologies such as CO2 Laser, Dermapen, Dermaroller and MMP®, delivers the desired medication to treat skin neoplasias and also acts in skin rejuvenation. Objective To treat BCC lesions using bleomycin via MMP®. Methods Ninety-eight BCC lesions in different anatomical areas were treated using MMP® technology to administer and uniformly distribute bleomycin throughout the lesion and in the established safety margin. Results The cure rate after six months was 96.94%; and recurrences were not associated with lesion size and/or depth. Adverse effects were the expected ones. Study limitations The follow-up time was only six months. Conclusion This therapeutic route showed to be promising and effective. |
| Keyword: | Bleomycin, Carcinoma, basal cell, Drug therapy, Skin neoplasms, Therapeutics |
| Texto completo: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
